Trial Profile
Memantine as an Adjunctive Agent to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Severe Major Depressive Episode
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- 28 Aug 2019 Status changed from active, no longer recruiting to completed.
- 11 Jan 2016 New trial record